凤凰网首页 手机凤凰网

凤凰卫视
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
免费注册
梅花生物(600873)公告正文

梅花生物:2016年第三季度报告

公告日期 2016-10-20
股票简称:梅花生物 股票代码:600873
             梅花生物 2016 年第三季度报告



  公司代码:600873               公司简称:梅花生物




梅花生物科技集团股份有限公司
      2016 年第三季度报告




                        1 / 18
                          梅花生物 2016 年第三季度报告




                                目 录
一、重要提示............................................................ 3


二、公司主要财务数据和股东变化.......................................... 3


三、重要事项............................................................ 5


四、附录................................................................ 8




                                     2 / 18
                                   梅花生物 2016 年第三季度报告


一、 重要提示

1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整,
      不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和连带的法律责任。

1.2 公司全体董事出席董事会审议季度报告。

1.3 公司负责人孟庆山、主管会计工作负责人李勇刚及会计机构负责人(会计主管人员)王爱
      玲保证季度报告中财务报表的真实、准确、完整。

1.4 本公司第三季度报告未经审计。

二、 公司主要财务数据和股东变化

2.1      主要财务数据

                                                                             单位:元 币种:人民币
                                                                                       本报告期末比上年度
                                 本报告期末                     上年度末
                                                                                           末增减(%)
总资产                          16,623,432,570.75                18,169,496,736.85                      -8.51
归属于上市公司股东的净资产       8,686,856,039.05                 8,333,151,774.94                      4.24
                               年初至报告期末             上年初至上年报告期末
                                                                                       比上年同期增减(%)
                                  (1-9 月)                   (1-9 月)
经营活动产生的现金流量净额       2,370,247,866.04                 2,562,811,209.88                      -7.51
                               年初至报告期末             上年初至上年报告期末           比上年同期增减
                                  (1-9 月)                   (1-9 月)                    (%)
营业收入                         7,927,851,633.42                 8,819,890,851.38                     -10.11
归属于上市公司股东的净利润         664,526,924.41                   383,528,008.72                     73.27
归属于上市公司股东的扣除非
                                   566,978,398.74                   274,632,032.44                   106.45
经常性损益的净利润
加权平均净资产收益率(%)                      7.79                             4.66    增加 3.13 个百分点
基本每股收益(元/股)                          0.21                             0.12                      75
稀释每股收益(元/股)                          0.21                             0.12                      75


非经常性损益项目和金额
√适用 □不适用
                                                                                单位:元 币种:人民币
                                               本期金额       年初至报告期末金额              说明
                  项目
                                          (7-9 月)              (1-9 月)
非流动资产处置损益                             -423,304.98             -1,365,675.24
越权审批,或无正式批准文件,或偶发性的
税收返还、减免
计入当期损益的政府补助,但与公司正常经
营业务密切相关,符合国家政策规定、按照     46,954,228.67               73,622,492.04
一定标准定额或定量持续享受的政府补助除


                                                 3 / 18
                                     梅花生物 2016 年第三季度报告



计入当期损益的对非金融企业收取的资金占
用费
企业取得子公司、联营企业及合营企业的投
资成本小于取得投资时应享有被投资单位可
辨认净资产公允价值产生的收益
非货币性资产交换损益
委托他人投资或管理资产的损益
因不可抗力因素,如遭受自然灾害而计提的
各项资产减值准备
债务重组损益
企业重组费用,如安置职工的支出、整合费
用等
交易价格显失公允的交易产生的超过公允价
值部分的损益
同一控制下企业合并产生的子公司期初至合
并日的当期净损益
与公司正常经营业务无关的或有事项产生的
损益
除同公司正常经营业务相关的有效套期保值
业务外,持有交易性金融资产、交易性金融
负债产生的公允价值变动损益,以及处置交       8,935,096.56           21,433,402.11
易性金融资产、交易性金融负债和可供出售
金融资产取得的投资收益
单独进行减值测试的应收款项减值准备转回
对外委托贷款取得的损益
采用公允价值模式进行后续计量的投资性房
地产公允价值变动产生的损益
根据税收、会计等法律、法规的要求对当期
损益进行一次性调整对当期损益的影响
受托经营取得的托管费收入
除上述各项之外的其他营业外收入和支出         1,916,874.84           10,757,068.91
其他符合非经常性损益定义的损益项目
所得税影响额                                -3,922,611.38           -6,736,962.84
少数股东权益影响额(税后)                     10,773.40              -161,799.31
                   合计                     53,471,057.11           97,548,525.67



2.2 截止报告期末的股东总数、前十名股东、前十名流通股东(或无限售条件股东)持股情况
       表

                                                                                    单位:股
股东总数(户)                                                                        206,871
                                         前十名股东持股情况


                                                4 / 18
                                        梅花生物 2016 年第三季度报告


     股东名称      期末持股数                   持有有限售条               质押或冻结情况
                                     比例(%)                                                            股东性质
     (全称)             量                    件股份数量             股份状态            数量
孟庆山              854,103,033         27.48        0                   质押            367,000,000   境内自然人
胡继军              248,469,341          7.99        0                    无                           境内自然人
杨维永                  78,810,526       2.54        0                    无                           境内自然人
王爱军                  71,316,274       2.29        0                    无                           境内自然人
中国证券金融股
                        57,944,132       1.86        0                   未知                           国有法人
份有限公司
梁宇博                  53,668,518       1.73        0                    无                           境内自然人
香港鼎晖生物科
                        40,125,120       1.29        0                   未知                           境外法人
技有限公司
全国社保基金一
                        31,455,975       1.01        0                   未知                             其他
一八组合
何君                    23,449,758       0.75        0                    无                           境内自然人
中央汇金资产管
                        19,292,700       0.62        0                   未知                           国有法人
理有限责任公司
                                        前十名无限售条件股东持股情况
                                                                                     股份种类及数量
             股东名称                 持有无限售条件流通股的数量
                                                                                  种类                 数量
孟庆山                                                   854,103,033       人民币普通股                854,103,033
胡继军                                                   248,469,341       人民币普通股                248,469,341
杨维永                                                    78,810,526       人民币普通股                 78,810,526
王爱军                                                    71,316,274       人民币普通股                 71,316,274
中国证券金融股份有限公司                                  57,944,132       人民币普通股                 57,944,132
梁宇博                                                    53,668,518       人民币普通股                 53,668,518
香港鼎晖生物科技有限公司                                  40,125,120       人民币普通股                 40,125,120
全国社保基金一一八组合                                    31,455,975       人民币普通股                 31,455,975
何君                                                      23,449,758       人民币普通股                 23,449,758
中央汇金资产管理有限责任公司                              19,292,700       人民币普通股                 19,292,700
上述股东关联关系或一致行动的说       上述股东中,孟庆山、杨维永、王爱军、何君为一致行动人,其他股东未知
明                                   其一致行动关系。



2.3 截止报告期末的优先股股东总数、前十名优先股股东、前十名优先股无限售条件股东持股
       情况表

□适用 √不适用

三、 重要事项

3.1 公司主要会计报表项目、财务指标重大变动的情况及原因

√适用 □不适用


                                                   5 / 18
                                                    梅花生物 2016 年第三季度报告


    1、 资产负债表项

                                                                                                       单位:万元 币种:人民币

         项目                   本报告期末        上年度期末         增减额       增减幅度%                       差异说明

                                                                                                   主要系本期经营活动现金流增加以及
       货币资金                 142,397.80        109,408.92       32,988.88          30.15
                                                                                                   减少玉米库存资金占用所致
       应收票据                 22,736.37         14,418.49         8,317.88          57.69        本期承兑收款增加所致
                                                                                                   主要系本期公司加快库存周转库存商
         存货                   79,208.81         127,553.37       -48,344.56        -37.90        品减少以及子公司通辽梅花及新疆梅
                                                                                                   花代储玉米减少及所致
     其他流动资产               13,967.27         75,157.95        -61,190.68        -81.42        主要系本期购买理财产品减少所致
                                                                                                   主要系本期公司子公司通辽梅花工程
       工程物资                   925.58            635.66           289.93           45.61
                                                                                                   物资增加所致
    其他非流动资产               4,634.46         14,755.40        -10,120.93        -68.59        主要系本期预付工程设备款减少所致
       应付票据                 20,000.00          2,400.00        17,600.00         733.33        主要系本期新增承兑汇票所致
                                                                                                   主要系本期子公司通辽梅花及新疆梅
       应交税费                  7,409.46          4,685.58         2,723.88          58.13
                                                                                                   花应交增值税增加所致
       应付利息                  9,229.25          6,224.11         3,005.14          48.28        主要系本期公司债券利息增加所致
                                                                                                   主要系本期子公司山西广生医药包装
       应付股利                  1,603.96              -            1,603.96         100.00
                                                                                                   股份有限公司应付分红款增加所致
一年内到期的非流动负债              -             70,454.98        -70,454.98        -100.00       主要系本期长期借款到期偿还所致
                                                                                                   主要系本期短融借款及非金融机构借
     其他流动负债               99,911.11         227,909.72       -127,998.60       -56.16
                                                                                                   款到期偿还所致

    2、 利润表项
                                                                                                  单位:万元 币种:人民币
     项目           本报告期        上年同期           增减额         增减幅度%                             差异说明
   财务费用         18,568.78       37,989.15         -19,420.37         -51.12        主要系本期借款减少利息支出减少所致
 资产减值损失          661.29           -498.31        1,159.60          232.71        本期计提坏账准备增加所致
                                                                                       主要系本期公司主材玉米原煤价格下降以及生
                                                                                       产标准化管理技术提升降低公司生产成本从而
    净利润          67,949.72       40,030.13         27,919.59          69.75
                                                                                       带动公司毛利增加,以及运费较同期减少及利息
                                                                                       支出减少所致

    3、 现金流量表项
                                                                                                  单位:万元 币种:人民币
                项目                      本报告期         上年同期         增减额       增减幅度%                 差异说明
                                                                                                          主要系本期收回上期理财本
  投资活动产生的现金流量净额              34,390.50        -30,224.38     64,614.88           213.78
                                                                                                          金及收益所致
  筹资活动产生的现金流量净额             -154,342.45       -268,023.52    113,681.06          42.41       主要系融资减少所致



    3.2 重要事项进展情况及其影响和解决方案的分析说明

    √适用 □不适用

                                                                   6 / 18
                                梅花生物 2016 年第三季度报告


    (1)控股股东孟庆山部分股权解除质押
    接控股股东孟庆山先生通知,孟庆山曾于 2014 年将其本人持有的 7000 万股无限售流通股质
押给中国进出口银行,为公司向该行融资提供抵押担保。截止本报告期末,公司已归还上述借款,
同时在中国登记结算有限公司上海分公司办理了质押解除手续。截止 2016 年 9 月 30 日,孟庆山
持有公司 854,103,033 股股份,占公司股份总数的 27.48%。已累计质押公司股份 367,000,000 股,
占其所持公司股份总数的 42.97%,占公司股份总数的 11.81%。
    (2)摘牌受让新疆招商梅花物流有限公司 70%股权进展情况
    经公司第七届董事会第二十七次会议审议通过,公司以自有资金摘牌受让招商局物流集团有
限公司持有的新疆招商梅花物流有限公司(简称招商梅花)70%的股权(详见往期定期报告及临
时公告),截止本报告出具日,上述受让股权事项已在新疆五家渠工商行政管理部门完成了股权
变更的登记手续,股权受让完成后,公司持有招商梅花 100%股权,招商梅花变为公司的全资子
公司。
    (3)公司债券付息情况
    2016 年 7 月 19 日,公司通过上海证券交易所网站对外发布了《2015 年公司债券(第一期)
2016 年付息公告》,就债券“15 梅花 01”付息相关事宜进行了公告。2015 年公司债券(第二期)付息
公告亦将于近期公告并兑付。

3.3 公司及持股 5%以上的股东承诺事项履行情况

√适用 □不适用
    公司及持股 5%以上股东承诺事项及其履行情况详见 2015 年度报告及 2016 年半年度报告中
重要事项章节部分。

3.4 预测年初至下一报告期期末的累计净利润可能为亏损或者与上年同期相比发生重大变动的
    警示及原因说明

√适用 □不适用
    受原材料价格下降等因素影响,截至 2016 年 9 月 30 日,公司实现归属于上市公司股东的净
利润 66452.69 万元,上年同期实现归属于上市公司股东的净利润为 38352.80 万元,同比增长 73.27%
(上述数据未经审计),而 2015 年度归属于上市公司股东的净利润 42545.68 万元,2016 年度公
司净利润同比可能会有较大增长,具体数据以 2016 年度报告为准。




                                           公司名称            梅花生物科技集团股份有限公司

                                          法定代表人                     孟庆山

                                             日期                       2016-10-19




                                           7 / 18
                                   梅花生物 2016 年第三季度报告


四、 附录

4.1 财务报表

                                    合并资产负债表
                                   2016 年 9 月 30 日
编制单位:梅花生物科技集团股份有限公司
                                             单位:元 币种:人民币 审计类型:未经审计
                      项目                                期末余额            年初余额
流动资产:
  货币资金                                                 1,423,977,976.27     1,094,089,150.34
  结算备付金
  拆出资金
  以公允价值计量且其变动计入当期损益的金融资产
  衍生金融资产
  应收票据                                                  227,363,746.20        144,184,866.16
  应收账款                                                  366,316,519.23        324,620,299.93
  预付款项                                                  515,644,536.21        628,038,862.31
  应收保费
  应收分保账款
  应收分保合同准备金
  应收利息
  应收股利
  其他应收款                                                767,704,425.51        808,360,744.76
  买入返售金融资产
  存货                                                      792,088,142.97      1,275,533,714.47
  划分为持有待售的资产
  一年内到期的非流动资产
  其他流动资产                                               139,672,703.31       751,579,514.28
    流动资产合计                                           4,232,768,049.70     5,026,407,152.25
非流动资产:
  发放贷款及垫款
  可供出售金融资产                                          294,519,754.00        292,619,754.00
  持有至到期投资
  长期应收款
  长期股权投资                                               71,437,850.72         73,604,279.69
  投资性房地产
  固定资产                                                10,918,017,652.57    11,508,669,076.44
  在建工程                                                   165,833,322.48       202,729,608.84
  工程物资                                                     9,255,830.91         6,356,572.06
  固定资产清理
  生产性生物资产
  油气资产
  无形资产                                                  731,643,482.27        759,159,385.19
  开发支出
  商誉                                                      143,173,700.39        143,173,700.39
  长期待摊费用
  递延所得税资产                                              10,438,284.80         9,223,215.42
  其他非流动资产                                              46,344,642.91       147,553,992.57
    非流动资产合计                                        12,390,664,521.05    13,143,089,584.60
      资产总计                                            16,623,432,570.75    18,169,496,736.85


                                                 8 / 18
                                   梅花生物 2016 年第三季度报告


流动负债:
  短期借款                                                1,513,556,000.00   1,516,155,546.79
  向中央银行借款
  吸收存款及同业存放
  拆入资金
  以公允价值计量且其变动计入当期损益的金融负债
  衍生金融负债
  应付票据                                                 200,000,000.00      24,000,000.00
  应付账款                                                 737,929,785.78     724,251,505.53
  预收款项                                                 351,510,665.68     477,568,647.91
  卖出回购金融资产款
  应付手续费及佣金
  应付职工薪酬                                              84,961,739.73      85,244,007.34
  应交税费                                                  74,094,639.92      46,855,815.24
  应付利息                                                  92,292,460.98      62,241,091.55
  应付股利                                                  16,039,602.00
  其他应付款                                               475,698,539.81     523,295,195.05
  应付分保账款
  保险合同准备金
  代理买卖证券款
  代理承销证券款
  划分为持有待售的负债
  一年内到期的非流动负债                                                       704,549,840.00
  其他流动负债                                              999,111,111.11   2,279,097,151.89
    流动负债合计                                          4,545,194,545.01   6,443,258,801.30
非流动负债:
  长期借款
  应付债券                                                2,985,674,325.16   2,982,674,871.53
  其中:优先股
          永续债
  长期应付款                                                20,000,000.00      20,000,000.00
  长期应付职工薪酬
  专项应付款
  预计负债
  递延收益                                                 163,407,965.06     164,053,083.44
  递延所得税负债
  其他非流动负债
    非流动负债合计                                        3,169,082,290.22   3,166,727,954.97
      负债合计                                            7,714,276,835.23   9,609,986,756.27
所有者权益
  股本                                                    3,108,226,603.00   3,108,226,603.00
  其他权益工具
  其中:优先股
          永续债
  资本公积                                                2,242,451,490.53   2,242,451,490.53
  减:库存股
  其他综合收益
  专项储备
  盈余公积                                                 251,942,321.38     251,942,321.38
  一般风险准备
  未分配利润                                              3,084,235,624.14   2,730,531,360.03
  归属于母公司所有者权益合计                              8,686,856,039.05   8,333,151,774.94


                                                 9 / 18
                                   梅花生物 2016 年第三季度报告


  少数股东权益                                             222,299,696.47        226,358,205.64
    所有者权益合计                                       8,909,155,735.52      8,559,509,980.58
      负债和所有者权益总计                              16,623,432,570.75     18,169,496,736.85
法定代表人:孟庆山     主管会计工作负责人:李勇刚      会计机构负责人:王爱玲
                                   母公司资产负债表
                                   2016 年 9 月 30 日
编制单位:梅花生物科技集团股份有限公司
                                               单位:元 币种:人民币 审计类型:未经审计
                  项目                                 期末余额             年初余额
流动资产:
  货币资金                                                 485,681,934.83       325,973,075.89
  以公允价值计量且其变动计入当期损益的金
融资产
  衍生金融资产
  应收票据                                                 191,216,607.25        81,064,889.93
  应收账款                                                 136,595,140.79       196,133,541.21
  预付款项                                                  49,264,106.00        84,802,683.28
  应收利息
  应收股利                                                                       300,000,000.00
  其他应收款                                             3,100,724,770.68      3,768,919,795.18
  存货                                                     100,484,528.54         48,416,488.59
  划分为持有待售的资产
  一年内到期的非流动资产
  其他流动资产                                              12,600,232.08        206,735,280.80
    流动资产合计                                         4,076,567,320.17      5,012,045,754.88
非流动资产:
  可供出售金融资产                                         260,519,754.00       258,619,754.00
  持有至到期投资
  长期应收款                                             3,143,588,916.37      3,040,807,796.06
  长期股权投资                                           5,415,715,750.72      5,417,882,179.69
  投资性房地产
  固定资产                                                 182,873,580.72       194,448,151.20
  在建工程
  工程物资
  固定资产清理
  生产性生物资产
  油气资产
  无形资产                                                  74,690,245.25        89,368,802.96
  开发支出
  商誉
  长期待摊费用
  递延所得税资产                                             2,179,030.74          1,403,615.80
  其他非流动资产
    非流动资产合计                                       9,079,567,277.80     9,002,530,299.71
      资产总计                                          13,156,134,597.97    14,014,576,054.59
流动负债:
  短期借款                                                 900,000,000.00       900,000,000.00
  以公允价值计量且其变动计入当期损益的金
融负债
  衍生金融负债
  应付票据                                                 200,000,000.00       151,000,000.00


                                             10 / 18
                                   梅花生物 2016 年第三季度报告


  应付账款                                                    666,982,352.11                  311,366,548.47
  预收款项                                                    217,366,674.09                  374,718,200.54
  应付职工薪酬                                                  8,965,208.44                    6,572,220.61
  应交税费                                                      4,295,047.29                   21,204,956.69
  应付利息                                                     87,252,485.42                   55,427,233.83
  应付股利
  其他应付款                                                 1,253,180,802.68                 983,953,907.09
  划分为持有待售的负债
  一年内到期的非流动负债                                                                       400,000,000.00
  其他流动负债                                                 999,111,111.11                1,698,716,618.66
    流动负债合计                                             4,337,153,681.14                4,902,959,685.89
非流动负债:
  长期借款
  应付债券                                                   2,985,674,325.16                2,982,674,871.53
  其中:优先股
          永续债
  长期应付款
  长期应付职工薪酬
  专项应付款
  预计负债
  递延收益
  递延所得税负债
  其他非流动负债
    非流动负债合计                                           2,985,674,325.16                2,982,674,871.53
      负债合计                                               7,322,828,006.30                7,885,634,557.42
所有者权益:
  股本                                                       3,108,226,603.00                3,108,226,603.00
  其他权益工具
  其中:优先股
          永续债
  资本公积                                                   2,185,149,123.18                2,208,701,622.94
  减:库存股
  其他综合收益
  专项储备
  盈余公积                                                    251,942,321.38                   251,942,321.38
  未分配利润                                                  287,988,544.11                   560,070,949.85
    所有者权益合计                                          5,833,306,591.67                 6,128,941,497.17
      负债和所有者权益总计                                 13,156,134,597.97                14,014,576,054.59
法定代表人:孟庆山           主管会计工作负责人:李勇刚                会计机构负责人:王爱玲

                                           合并利润表
                                         2016 年 1—9 月
编制单位:梅花生物科技集团股份有限公司
                                                    单位:元 币种:人民币 审计类型:未经审计
                                                                         年初至报告期期     上年年初至报告
                                   本期金额               上期金额
            项目                                                        末金额(1-9 月)    期期末金额(1-9
                                   (7-9 月)         (7-9 月)
                                                                                                  月)
一、营业总收入                   2,506,915,324.53   2,660,467,101.39     7,927,851,633.42    8,819,890,851.38
其中:营业收入                   2,506,915,324.53   2,660,467,101.39     7,927,851,633.42    8,819,890,851.38


                                                11 / 18
                                       梅花生物 2016 年第三季度报告


       利息收入
       已赚保费
       手续费及佣金收入
二、营业总成本                       2,276,546,333.10   2,635,988,804.70   7,271,021,486.82   8,433,150,366.05
其中:营业成本                       1,865,232,342.28   2,145,617,494.23   6,008,825,930.28   7,015,375,895.37
       利息支出
       手续费及佣金支出
       退保金
       赔付支出净额
       提取保险合同准备金净额
       保单红利支出
       分保费用
       营业税金及附加                  17,697,337.79        8,724,000.46     45,882,341.09      37,782,568.63
       销售费用                       178,910,142.97     189,577,685.99     565,011,348.92     620,423,291.90
       管理费用                       151,268,674.64     150,145,169.80     459,001,142.96     384,660,169.34
       财务费用                        63,490,616.88     141,758,620.47     185,687,842.48     379,891,530.43
       资产减值损失                        -52,781.46        165,833.75       6,612,881.09       -4,983,089.62
  加:公允价值变动收益(损失以
“-”号填列)
       投资收益(损失以“-”号填
                                       10,071,721.12        4,108,479.19     20,491,716.71      28,486,278.57
列)
       其中:对联营企业和合营企
                                        1,136,624.56        1,238,022.59       -941,685.40       -2,782,380.25
业的投资收益
       汇兑收益(损失以“-”号填
列)
三、营业利润(亏损以“-”号填列)    240,440,712.55      28,586,775.88     677,321,863.31     415,226,763.90
  加:营业外收入                       49,600,959.86      44,172,827.61      85,870,728.75      91,436,055.96
       其中:非流动资产处置利得            66,726.56           4,784.90         152,909.64          30,151.71
  减:营业外支出                        1,153,161.33        1,840,847.60      2,856,843.04       3,407,041.99
       其中:非流动资产处置损失           490,031.54         676,589.61       1,518,584.88         896,858.48
四、利润总额(亏损总额以“-”号
                                      288,888,511.08      70,918,755.89     760,335,749.02     503,255,777.87
填列)
  减:所得税费用                       23,596,433.28      19,925,844.47      80,838,544.50     102,954,462.25
五、净利润(净亏损以“-”号填列)    265,292,077.80      50,992,911.42     679,497,204.52     400,301,315.62
  归属于母公司所有者的净利润          260,431,050.69      45,500,978.42     664,526,924.41     383,528,008.72
  少数股东损益                          4,861,027.11        5,491,933.00     14,970,280.11      16,773,306.90
六、其他综合收益的税后净额
  归属母公司所有者的其他综合收
益的税后净额
    (一)以后不能重分类进损益
的其他综合收益


                                                  12 / 18
                                        梅花生物 2016 年第三季度报告


        1.重新计量设定受益计划净
 负债或净资产的变动
        2.权益法下在被投资单位不
 能重分类进损益的其他综合收益中
 享有的份额
     (二)以后将重分类进损益的
 其他综合收益
        1.权益法下在被投资单位以
 后将重分类进损益的其他综合收益
 中享有的份额
        2.可供出售金融资产公允价
 值变动损益
        3.持有至到期投资重分类为
 可供出售金融资产损益
        4.现金流量套期损益的有效
 部分
        5.外币财务报表折算差额
        6.其他
   归属于少数股东的其他综合收益
 的税后净额
 七、综合收益总额                       265,292,077.80          50,992,911.42      679,497,204.52        400,301,315.62
   归属于母公司所有者的综合收益
                                        260,431,050.69          45,500,978.42      664,526,924.41        383,528,008.72
 总额
   归属于少数股东的综合收益总额           4,861,027.11           5,491,933.00        14,970,280.11        16,773,306.90
 八、每股收益:
 (一)基本每股收益(元/股)                          0.08                 0.01                   0.21               0.12
 (二)稀释每股收益(元/股)                          0.08                 0.01                   0.21               0.12


 本期发生同一控制下企业合并的,被合并方在合并前实现的净利润为:0 元, 上期被合并方实现
 的净利润为: 0 元。

 法定代表人:孟庆山              主管会计工作负责人:李勇刚                   会计机构负责人:王爱玲


                                      母公司利润表
                                     2016 年 1—9 月
 编制单位:梅花生物科技集团股份有限公司
                                             单位:元 币种:人民币 审计类型:未经审计
                                                                                年初至报告期期末       上年年初至报告期
                                   本期金额                 上期金额
           项目                                                                       金额                期末金额
                                   (7-9 月)               (7-9 月)
                                                                                   (1-9 月)             (1-9 月)
一、营业收入                     1,565,201,708.99          1,795,857,195.63       5,012,726,516.02       5,767,368,670.79
  减:营业成本                   1,414,081,551.32          1,648,366,584.30       4,526,710,353.59       5,349,805,579.13

                                                     13 / 18
                                       梅花生物 2016 年第三季度报告


         营业税金及附加              337,459.21              510,791.88     3,394,180.16     6,125,245.12
         销售费用                 111,041,646.05      121,153,206.83      346,785,724.10   379,735,749.50
         管理费用                  41,588,687.62       32,161,886.31      116,654,249.92    87,407,309.49
         财务费用                   1,310,642.71             310,553.03      -665,613.47    -2,718,379.73
         资产减值损失                                                       5,169,432.98    -5,395,544.02
  加:公允价值变动收益(损
失以“-”号填列)
         投资收益(损失以“-”
                                    3,027,440.67        2,186,136.62        6,955,748.97    24,597,280.90
号填列)
         其中:对联营企业和合
                                    1,136,624.56        1,238,022.59         -941,685.40    -2,782,380.25
营企业的投资收益
二、营业利润(亏损以“-”号
                                     -130,837.25        -4,459,690.10      21,633,937.71   -22,994,007.80
填列)
  加:营业外收入                   14,826,820.07        3,357,843.33       16,434,506.91     5,412,284.57
         其中:非流动资产处置
                                                                                3,659.54         9,932.63
利得
  减:营业外支出                       70,781.75        1,019,471.84         103,605.00      2,101,138.07
         其中:非流动资产处置
                                        1,166.49               2,977.32         9,451.56         3,483.09
损失
三、利润总额(亏损总额以“-”
                                   14,625,201.07        -2,121,318.61      37,964,839.62   -19,682,861.30
号填列)
    减:所得税费用                                                           -775,414.94      809,723.53
四、净利润(净亏损以“-”号
                                   14,625,201.07        -2,121,318.61      38,740,254.56   -20,492,584.83
填列)
五、其他综合收益的税后净额
  (一)以后不能重分类进损
益的其他综合收益
    1.重新计量设定受益计划
净负债或净资产的变动
    2.权益法下在被投资单位
不能重分类进损益的其他综合
收益中享有的份额
  (二)以后将重分类进损益
的其他综合收益
    1.权益法下在被投资单位
以后将重分类进损益的其他
综合收益中享有的份额
    2.可供出售金融资产公允
价值变动损益
    3.持有至到期投资重分类
为可供出售金融资产损益
    4.现金流量套期损益的有

                                                   14 / 18
                                      梅花生物 2016 年第三季度报告


效部分
    5.外币财务报表折算差额
    6.其他
六、综合收益总额                  14,625,201.07        -2,121,318.61        38,740,254.56      -20,492,584.83
七、每股收益:
(一)基本每股收益(元/股)
(二)稀释每股收益(元/股)

 法定代表人:孟庆山           主管会计工作负责人:李勇刚               会计机构负责人:王爱玲

                                   合并现金流量表
                                     2016 年 1—9 月
 编制单位:梅花生物科技集团股份有限公司
                                             单位:元 币种:人民币 审计类型:未经审计
                                                   年初至报告期期末金额         上年年初至报告期期末金额
                      项目
                                                         (1-9 月)                     (1-9 月)
 一、经营活动产生的现金流量:
   销售商品、提供劳务收到的现金                              7,871,741,278.94               9,009,691,769.15
   客户存款和同业存放款项净增加额
   向中央银行借款净增加额
   向其他金融机构拆入资金净增加额
   收到原保险合同保费取得的现金
   收到再保险业务现金净额
   保户储金及投资款净增加额
   处置以公允价值计量且其变动计入当期损益
 的金融资产净增加额
   收取利息、手续费及佣金的现金
   拆入资金净增加额
   回购业务资金净增加额
   收到的税费返还                                               57,579,785.79                 64,689,434.80
   收到其他与经营活动有关的现金                               196,484,054.20                  97,127,383.70
     经营活动现金流入小计                                    8,125,805,118.93               9,171,508,587.65
   购买商品、接受劳务支付的现金                              3,876,717,905.58               4,682,533,574.19
   客户贷款及垫款净增加额
   存放中央银行和同业款项净增加额
   支付原保险合同赔付款项的现金
   支付利息、手续费及佣金的现金
   支付保单红利的现金
   支付给职工以及为职工支付的现金                             525,258,123.43                 584,513,621.70
   支付的各项税费                                             508,734,258.62                 430,052,100.55
   支付其他与经营活动有关的现金                               844,846,965.26                 911,598,081.33
     经营活动现金流出小计                                    5,755,557,252.89               6,608,697,377.77


                                                  15 / 18
                                   梅花生物 2016 年第三季度报告


      经营活动产生的现金流量净额                        2,370,247,866.04           2,562,811,209.88
二、投资活动产生的现金流量:
  收回投资收到的现金                                     566,900,000.00
  取得投资收益收到的现金                                  21,715,435.10              31,268,658.82
  处置固定资产、无形资产和其他长期资产收回
                                                             407,644.64                 681,284.00
的现金净额
  处置子公司及其他营业单位收到的现金净额                                             20,000,000.00
  收到其他与投资活动有关的现金                                                      200,000,000.00
    投资活动现金流入小计                                 589,023,079.74             251,949,942.82
  购建固定资产、无形资产和其他长期资产支付
                                                         187,700,588.76             354,559,882.85
的现金
  投资支付的现金                                          57,417,473.00             199,633,858.79
  质押贷款净增加额
  取得子公司及其他营业单位支付的现金净额
  支付其他与投资活动有关的现金
    投资活动现金流出小计                                 245,118,061.76             554,193,741.64
      投资活动产生的现金流量净额                         343,905,017.98             -302,243,798.82
三、筹资活动产生的现金流量:
  吸收投资收到的现金                                                                 63,800,000.00
  其中:子公司吸收少数股东投资收到的现金                                             63,800,000.00
  取得借款收到的现金                                    2,431,293,828.35           6,458,167,832.48
  发行债券收到的现金                                                               1,500,000,000.00
  收到其他与筹资活动有关的现金                           948,045,471.98             379,864,452.87
    筹资活动现金流入小计                                3,379,339,300.33           8,401,832,285.35
  偿还债务支付的现金                                    4,058,226,617.50          10,092,821,017.95
  分配股利、利润或偿付利息支付的现金                     482,894,514.94             668,629,808.39
  其中:子公司支付给少数股东的股利、利润
  支付其他与筹资活动有关的现金                           381,642,691.43             320,616,612.57
    筹资活动现金流出小计                                4,922,763,823.87          11,082,067,438.91
      筹资活动产生的现金流量净额                       -1,543,424,523.54          -2,680,235,153.56
四、汇率变动对现金及现金等价物的影响                       7,205,937.43              36,647,403.22
五、现金及现金等价物净增加额                            1,177,934,297.91            -383,020,339.28
  加:期初现金及现金等价物余额                           245,643,678.36             559,553,015.97
六、期末现金及现金等价物余额                            1,423,577,976.27            176,532,676.69

法定代表人:孟庆山         主管会计工作负责人:李勇刚             会计机构负责人:王爱玲


                                  母公司现金流量表
                                    2016 年 1—9 月
编制单位:梅花生物科技集团股份有限公司
                                            单位:元 币种:人民币 审计类型:未经审计

                                             16 / 18
                                   梅花生物 2016 年第三季度报告


                                               年初至报告期期末金额        上年年初至报告期期末金额
                   项目
                                                    (1-9 月)                    (1-9 月)
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金                          4,753,547,661.71             5,749,454,966.95
  收到的税费返还
  收到其他与经营活动有关的现金                          3,026,507,961.43             5,190,246,304.48
    经营活动现金流入小计                                7,780,055,623.14            10,939,701,271.43
  购买商品、接受劳务支付的现金                          3,987,350,380.27             5,444,871,967.60
  支付给职工以及为职工支付的现金                          40,481,298.23                 45,084,856.21
  支付的各项税费                                          59,125,077.39                 90,091,256.17
  支付其他与经营活动有关的现金                          3,047,556,603.07             4,312,142,786.61
    经营活动现金流出小计                                7,134,513,358.96             9,892,190,866.59
  经营活动产生的现金流量净额                             645,542,264.18              1,047,510,404.84
二、投资活动产生的现金流量:
  收回投资收到的现金                                     195,200,000.00
  取得投资收益收到的现金                                 309,122,177.94                327,379,661.15
  处置固定资产、无形资产和其他长期资产收回
                                                             210,000.00                        20,000.00
的现金净额
  处置子公司及其他营业单位收到的现金净额
  收到其他与投资活动有关的现金                                                         200,000,000.00
    投资活动现金流入小计                                 504,532,177.94                527,399,661.15
  购建固定资产、无形资产和其他长期资产支付
                                                          27,928,097.53                 32,281,071.00
的现金
  投资支付的现金                                          73,969,972.76                117,700,000.00
  取得子公司及其他营业单位支付的现金净额
  支付其他与投资活动有关的现金
    投资活动现金流出小计                                 101,898,070.29                149,981,071.00
      投资活动产生的现金流量净额                         402,634,107.65                377,418,590.15
三、筹资活动产生的现金流量:
  吸收投资收到的现金
  取得借款收到的现金                                    1,689,000,000.00             5,716,930,872.35
  收到其他与筹资活动有关的现金                          2,357,678,066.67             5,686,000,000.00
    筹资活动现金流入小计                                4,046,678,066.67            11,402,930,872.35
  偿还债务支付的现金                                    2,789,000,000.00             6,581,930,872.35
  分配股利、利润或偿付利息支付的现金                     463,009,180.78                584,257,402.97
  支付其他与筹资活动有关的现金                          1,434,900,000.00             5,679,105,885.00
    筹资活动现金流出小计                                4,686,909,180.78            12,845,294,160.32
      筹资活动产生的现金流量净额                         -640,231,114.11             -1,442,363,287.97
四、汇率变动对现金及现金等价物的影响                                1.22                       91,904.20
五、现金及现金等价物净增加额                             407,945,258.94                -17,342,388.78
  加:期初现金及现金等价物余额                            77,736,675.89                 42,198,920.79

                                             17 / 18
                                 梅花生物 2016 年第三季度报告


六、期末现金及现金等价物余额                           485,681,934.83               24,856,532.01


法定代表人:孟庆山       主管会计工作负责人:李勇刚        会计机构负责人:王爱玲




4.2 审计报告

□适用 √不适用




                                           18 / 18
数据加载中...
prevnext
手机查看股票